Company

ABOUT LS CancerDiag

Our Company values

LS CancerDiag Ltd is committed to reducing cancer mortality rates with a simple and accurate diagnostic method that detects Lynch syndrome, the world’s most common inherited cancer predisposition, even before tumors develop. Our vision is to see DiagMMR® as a new global testing standard in Lynch syndrome diagnostics.

Lynch syndrome is the main cause of hereditary cancers with a broad spectrum of tumors, the most prominent being colorectal and endometrial cancers. With around 1 in 300 people of the world’s population carrying the Lynch syndrome mutation, there are  millions of people under a severe risk for being affected by Lynch syndrome.

Our groundbreaking DiagMMR® assay is an unique functional test that can be used for diagnosis of MMR deficiency i.e. Lynch syndrome (previously known as Hereditary Non­Polyposis Colorectal Cancer; HNPCC).

Our mission is to confirm or exclude Lynch syndrome, provide actionable results and help prevent cancer through an innovation that dramatically simplify diagnostics of Lynch syndrome by delivering predictive, reliable and accurate results.

  • We respect healthy life
  • We create and share knowledge
  • We commit to trust and quality
LS CancerDiag is based in Helsinki

LS CancerDiag is based in Finland and was founded as a
spin-off from the University of Helsinki.

Lynch syndrome is characterized by an inherited functional deficiency in a mismatch repair (MMR) proteins. The genes encoding for MMR proteins have been identified and studied for many years. Our founder and CEO Prof. Minna Nyström is an internationally distinguished expert in that field and back  in the 90s, when she started to use sequencing as a novel method to enable disease causing mutation finding in the susceptibility genes, she already saw possible limitations in the method.

She realized that knowing the DNA sequence change, while being useful information, would not reveal the actual malfunction of the encoded MMR proteins, unless it was possible to test for exactly that. So she set out to develop such a method. DiagMMR® is the result of many years of dedicated research to get to the point, where MMR functionality, and functional deficiency typical to Lynch syndrome, can be analyzed directly without the need of any underlying clinical data. It can therefore help medical professionals and patients alike, by providing actionable results and help answering questions that remained unanswered to this day.

This new method supports the trend and the need to combine existing data with new insights and data points to enable more personalized treatments and preventive measures in the fight against cancer. 

2013

Founding year

LS CancerDiag is founded as a spin-off from the University of Helsinki, also thanks to an ERC grant.

2013

2015

First patent granted in Australia

Australia is the first country to grant the patent to LS CancerDiag for the DiagMMR® innovation.

2015

2016

Clinical validation begins

The clinical study to validate DiagMMR® is initiated with the central hopsitals of Helsinki and Jyväskylä.

2016

2018

Clinical validation completed

The extensive clinical validation is complete with excellent accuracy results.

2018

2019

CE mark as IVD MD obtained

DiagMMR® is CE marked as in vitro diagnostics medical device.

2019

2019

Launch to domestic market

DiagMMR® is launched in the Finnish market in collaboration with two distribution partners.

2019

2020

LS CancerDiag receives international attention.

LS CancerDiag is selected for various programmes across Europe for supporting the new phase of growth.

2020